BLEND (Fluent) 24-hour amplitude 184.6%: Upbit listing drives surge over 140%
Bitget Pulse2026/04/29 16:02Volatility Overview
In the past 24 hours, BLEND's price surged from a low of $0.09004 to a high of $0.25624, currently quoted at $0.17074, with an amplitude of 184.6%. Trading volume skyrocketed by more than 1000%, reaching approximately $153 million, with a significant net capital inflow and a considerable increase in liquidity.
Brief Analysis of Abnormal Fluctuations
• Upbit officially launched BLEND/KRW and BLEND/BTC trading pairs on April 29, 2026, directly triggering a 142.7% hourly surge in price and a trading volume explosion.
• Synergistic effect of multiple exchange listings, including recent support from Kraken and other platforms, has further amplified liquidity and demand.
Market View and Outlook
Market sentiment is highly optimistic, with the community focusing on the Upbit listing-driven discovery effect and liquidity injection. Early NFT holders have already realized over 2x gains. Analysts predict a potential short-term touch of $0.40 but warn of pullback risks after an RSI above 90 and massive green candles, advising attention to support levels.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs
Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.
Fed Officials Turn Hawkish: Daly Says Supply Shocks Should No Longer Be "Wait-and-See," Hammack Suggests More Aggressive Rate Hikes May Be Needed if Inflation Expectations Become Entrenched
San Francisco Fed President Daly stated that the traditional "wait and see" approach to supply-side shocks has been abandoned, noting that businesses in her district are tending to pass rising costs on to consumers and that current inflation risks are "skewed fully to the upside." Cleveland Fed President Hammack said that once the public forms an "inflationary mindset," the difficulty of monetary policy regulation will increase significantly, and the required interest rate hikes will then exceed expectations.
Australian Dollar crumbles as job losses shatter RBA rate hike hopes
Over $10 billion in market value evaporated in four trading days as CoreWeave (CRWV.US) debt risks trigger sell-off, but Deutsche Bank sees it as a buying opportunity
Deutsche Bank believes that the recent sell-off of CoreWeave lacks sufficient company fundamentals to justify it, and the sharp price correction has instead created a buying opportunity for investors.
Crypto prices
More
